Belyntic

Belyntic is an early-stage, preclinical biotech company pioneering a novel vaccine platform called T-Fender, designed to induce strong and lasting cellular (T cell) immunity. The company is initially targeting latent viral infections like Cytomegalovirus (CMV) and John Cunningham virus (JCV) in immunocompromised patients, a population with high unmet medical need. Led by a small, dual-managing director team, Belyntic is actively seeking partnerships to advance its portfolio and drive innovation in the field of T cell-inducing vaccines.

T-Fender platform: a vaccine technology based on self-adjuvant, self-aggregating synthetic long peptides (SLPs) designed to induce potent and durable cellular (T cell) immune responses. The platform utilizes AI for candidate design.

Belyntic competes in the broad field of therapeutic vaccines and T cell immunotherapies against large pharma and biotech firms using mRNA, viral vector, and other peptide-based platforms. Its niche focus on synthetic long peptides with integrated adjuvants is a specific differentiation, but clinical validation will be required to establish a competitive edge.